Gaurisankar Sa, Ph.D.

Professor Gaurisankar Sa, Fellow of National Academy of Science, India, Fellow of Nanyang Academy of Science, Singapore, Fellow of West Bengal Academy of Science and Technology, received his Doctoral degrees in Biochemistry from University of Calcutta, in 1989. Then he joined Virginia Tech, USA as visiting faculty. Thereafter he moved to Cleveland Clinic, USA to work on cell signaling. In 1994 he joined Bose Institute, India where he is now working as a Professor and Chairman of Molecular Medicine. He is also a visiting professor of The Cleveland Clinic, USA. Prof. Sa is the Editor-in–Chief of International J Immunology, Sectional Editor of Scientific Reports, Future Oncology, PNAS, India, Editor of J Cancer Research & Molecular Medicine, Austin J. Clinical Immunology, Head & Face Medicine and Editorial board member of no of Scientific Journals like Int. J. Cancer Res., J Pharmacology & Toxicology, Advances in Modern Oncology Research etc. Research work of Prof. Sa is focused in the area of, cancer biology and tumor immunology and understanding its molecular mechanisms. His work basically aimed at development of safe and non-toxic anti-cancer drug and development of adjuvant immunotherapy. His recent work also aims at understanding the mechanisms of immune-evasion of cancer so that immunotherapy can be reinforce into cancer patients. His findings are highly recognized by various National and International Scientific Communities as is evident from his more than 150 publications in high-impact journals, receiving various National/International awards, and granting number of patents.


Cancer Vaccine: Past, present and future

Gaurisankar Sa

Professor of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India


Advances in molecular technology also secured the use of genetically modified genes or proteins of interest to enhance the chance of stronger immune responses. The formulation of vaccines to increase chances of immune recognition such as nanoparticles for peptide delivery is another area of great interest. Studies indicate that cancer vaccines alone may elicit tumor-specific cellular or humoral responses in immunologic assays and even regression or shrinkage of the cancer in select trials, but novel strategies, especially in combination with other cancer therapies, are under study and are likely to be critical to achieve and optimize reliable objective responses and survival benefit. In this review, cancer vaccine platforms with different approaches to deliver tumor antigens and boost immunity are discussed with the intention of summarizing what we know and what we need to improve in the clinical trial setting.